Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Colorectal Neoplasms × Crizotinib × Clear all

Phase

Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 14 Lung Neoplasms 5 Multiple Myeloma 4 Lymphoma 3 Lymphoma, Large-Cell, Anaplastic 2 Hematologic Neoplasms 2 Adenocarcinoma 2 Uveal Melanoma 1 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Sarcoma, Clear Cell 1 Sarcoma, Alveolar Soft Part 1 Rhabdomyosarcoma, Alveolar 1 Relapsed Pediatric Solid Tumor 1 Rare Tumor 1 Neoplasms 1 Neoplasm Metastasis 1 Lymphoma, Non-Hodgkin 1 Lung Adenocarcinoma Metastatic 1 Granuloma, Plasma Cell 1 Gallbladder Neoplasms 1 Endometrial Cancer Recurrent 1 Colorectal Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Renal Cell 1 Adenocarcinoma of Lung 1

Interventions

Bevacizumab 191 Fluorouracil 186 Oxaliplatin 179 Irinotecan 178 Leucovorin 167 Capecitabine 126 Cetuximab 120 Panitumumab 59 Folfox protocol 41 regorafenib 35 Radiotherapy 35 IFL protocol 33 pembrolizumab 32 HMPL-013 29 Nivolumab 26 trifluridine tipiracil drug combination 25 Neoadjuvant Therapy 23 Drug Therapy 20 Celecoxib 16 tislelizumab 15 aflibercept 14 XELOX 14 sintilimab 13 Trifluridine 13 Trastuzumab 13 Gemcitabine 13 Chemotherapy, Adjuvant 13 durvalumab 12 atezolizumab 12 Floxuridine 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05725200 2023-02-21

EVIDENT

Oslo University Hospital

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡